Overriding drug and medical technology patents for pandemic recovery: A legitimate move for high-income countries, too

Open Access
Authors
Publication date 04-2021
Journal BMJ Global Health
Article number e005518
Volume | Issue number 6 | 4
Number of pages 4
Organisations
  • Faculty of Law (FdR)
Abstract

Compulsory licenses are legal tools to override patent-protection on medicines and medical technologies. Compulsory licenses can help scale up the production and lower prices of patent-protected medicines while still accounting for the patent holder’s interests.

Compulsory licensing is making a comeback in high-income countries as a negotiation strategy and a legal tool to remedy high prices and/or supply shortages of medicines and medical technologies.

High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now.

Document type Comment/Letter to the editor
Language English
Published at https://doi.org/10.1136/bmjgh-2021-005518
Other links https://www.scopus.com/pages/publications/85103898285
Downloads
e005518.full (Final published version)
Permalink to this page
Back